At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed May 20, 2026 at 08:00 ET
Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study recognized as a Poster of Distinction. The data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic care, but no new regulatory actions or financial guidance were provided.
- 31 vonoprazan-related abstracts presented at DDW 2026, including 28 independent investigator-initiated studies
- Phathom-sponsored analysis from Phase 3 pHalcon-NERD-301 study recognized as Poster of Distinction
- Data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic submucosal dissection use
- No new FDA decisions, label expansions, or financial updates announced
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access